Observations on neonatal mortality.

D. Bowden,A. Goodfellow,C. E. Snelling

1956-12-15

Canadian Medical Association Journal

Abstract:

What problem does this paper attempt to address?

Dissecting the Clinicopathological, Genomic, and Prognostic Significance of ALK Rearrangement in Resected Lung Adenocarcinoma

Hang Cao,Wangyang Zhu,Huatao Tang,Chaoqiang Deng,Fangqiu Fu,Yuan Li,Yang Zhang,Haiquan Chen

DOI: https://doi.org/10.1016/j.jtcvs.2024.09.020

2024-01-01

Abstract:Objectives The ALINA trial introduced anaplastic lymphoma kinase (ALK) inhibitors in an early-stage context, generating notable interest. This study aims to investigate the characteristics and prognostic implications of ALK rearrangement in patients with resected lung adenocarcinoma (LUAD). Methods We retrospectively evaluated resected LUAD cases with documented ALK status from 2008 to 2020. The association between ALK positivity and clinicopathological characteristics, molecular profiles, and outcomes was explored. Results Among 4944 cases, 238 (4.8%) were ALK-positive, correlating with younger age and non-smokers. ALK positivity was also significantly associated with pure-solid nodules, spread through air spaces, and solid-predominant adenocarcinoma. ALK-positive tumors exhibited an overall low frequency of co-mutations (e.g., TP53, STK11). ALK positivity was associated with inferior recurrence-free survival (RFS) in stage I patients who did not receive adjuvant chemotherapy while with prolonged RFS in stage II and III patients who received adjuvant chemotherapy. Notably, six patients treated with adjuvant ALK inhibitors experienced no recurrence or metastasis during the follow-up period. Additionally, the administration of ALK inhibitors significantly improved post-recurrence survival in ALK-positive patients. Conclusions ALK positivity was associated with specific aggressive pathological features and inferior RFS in stage I LUAD. ALK-positive patients seemed to benefit more from adjuvant chemotherapy. Active treatment with ALK inhibitors or chemotherapy should be considered for ALK-positive LUAD, although further evidence is warranted to expand their utility in early-stage disease management.
Concomitant Mutation Status of ALK-rearranged Non-Small Cell Lung Cancers and Its Prognostic Impact on Patients Treated with Crizotinib

Jingjing Li,Bin Zhang,Yu Zhang,Feng Xu,Zhenfa Zhang,Lin Shao,Chunhe Yan,Paola Ulivi,Marc G. Denis,Petros Christopoulos,Vincent Thomas de Montpreville,Eric H. Bernicker,Anthonie J. van der Wekken,Changli Wang,Dongsheng Yue

DOI: https://doi.org/10.21037/tlcr-21-160

2021-01-01

Translational Lung Cancer Research

Abstract:BACKGROUND:In non-small cell lung cancer (NSCLC), anaplastic lymphoma kinase (ALK) rearrangement characterizes a subgroup of patients who show sensitivity to ALK tyrosine kinase inhibitors (TKIs). However, the prognoses of these patients are heterogeneous. A better understanding of the genomic alterations occurring in these tumors could explain the prognostic heterogeneity observed in these patients.METHODS:We retrospectively analyzed 96 patients with NSCLC with ALK detected by immunohistochemical staining (VENTANA anti-ALK(D5F3) Rabbit Monoclonal Primary Antibody). Cancer tissues were subjected to next-generation sequencing using a panel of 520 cancer-related genes. The genomic landscape, distribution of ALK fusion variants, and clinicopathological characteristics of the patients were evaluated. The correlations of genomic alterations with clinical outcomes were also assessed.RESULTS:Among the 96 patients with immunohistochemically identified ALK fusions, 80 (83%) were confirmed by next-generation sequencing. TP53 mutation was the most commonly co-occurring mutation with ALK rearrangement. Concomitant driver mutations [2 Kirsten rat sarcoma viral oncogene homolog (KRAS) G12, 1 epidermal growth factor receptor (EGFR) 19del, and 1 MET exon 14 skipping] were also observed in 4 adenocarcinomas. Echinoderm microtubule associated protein-like 4 (EML4)-ALK fusions were identified in 95% of ALK-rearranged patients, with 16.2% of them also harboring additional non-EML4-ALK fusions. Nineteen non-EML4 translocation partners were also discovered, including 10 novel ones. Survival analyses revealed that patients concurrently harboring PIK3R2 alterations showed a trend toward shorter progression-free survival (6 vs. 13 months, P=0.064) and significantly shorter overall survival (11 vs. 32 months, P=0.004) than did PIK3R2-wild-type patients. Patients with concomitant alterations in PI3K the signaling pathway also had a shorter median overall survival than those without such alterations (23 vs. 32 months, P=0.014), whereas progression-free survival did not differ significantly.CONCLUSIONS:The spectrum of ALK-fusion variants and the landscape of concomitant genomic alterations were delineated in 96 NSCLC patients. Our study also demonstrated the prognostic value of concomitant alterations in crizotinib-treated patients, which could facilitate improved stratification of ALK-rearranged NSCLC patients in the selection of candidates who could optimally benefit from therapy.
Clinicopathological and prognostic implications of ALK rearrangement in patients with completely surgically resected lung adenocarcinoma

Huan Zhang,Guangyao Shan,Benjie Cai,Guoshu Bi,Zhencong Chen,Jiaqi Liang,Valeria Besskaya,Yuansheng Zheng,Weigang Guo,Lin Wang,Songtao Xu,Cheng Zhan

DOI: https://doi.org/10.1111/1759-7714.14170

IF: 3.223

2021-10-01

Thoracic Cancer

Abstract:BackgroundThe prognostic significance of ALK rearrangement is still contradictory. Here, we aimed to investigate the clinical characteristics and outcomes of lung adenocarcinoma patients with ALK rearrangement, and analyze whether these patients benefited from targeted therapy. MethodsThis was a retrospective cohort study of 80 ALK-rearranged lung adenocarcinoma patients who had undergone radical surgery and another 3031 ALK mutation-negative patients were retrospectively reviewed for inclusion in this case-controlled analyses. Overall survival (OS) was evaluated using the Kaplan-–Meier method. Univariate analysis (UVA) and multivariate analysis (MVA) by the Cox proportional hazards regression identified risk factors that predicted OS. ResultsCompared to ALK-negative patients, the ALK rearranged patients were younger, with more non-smokers, more females, a larger primary tumor was demonstrated, and were a higher pathological stage. In particular, the risk of lymph node metastasis was higher. For patients with surgically-resected tumors, the prognosis was better for ALK rearranged patients (HR = 0.503; 95% CI: 0.259–0.974, p = 0.041). In addition, for stage II–III patients, targeted therapy was an independent prognostic factor of better OS (HR = 0.159; 95% CI: 0.032–0.801, p = 0.026). ConclusionsALK rearranged lung adenocarcinoma patients who have undergone radical surgery have distinct clinical features. Patients with ALK rearrangement may have a favorable prognosis, and stage II–III patients may benefit from targeted treatment.

oncology,respiratory system
Clinical Characteristics and Outcomes of Patients with Primary Lung Adenocarcinoma Harboring Alk Rearrangements Detected by Fish, Ihc, and Rt-Pcr

Jinghui Wang,Yiran Cai,Yujie Dong,Jingying Nong,Lijuan Zhou,Guimei Liu,Dan Su,Xi Li,Shafei Wu,Xuejing Chen,Na Qin,Xuan Zeng,Haiqing Zhang,Zongde Zhang,Shucai Zhang

DOI: https://doi.org/10.1371/journal.pone.0101551

IF: 3.7

2014-01-01

PLoS ONE

Abstract:EML4-ALK is a new driver gene of non-small cell lung cancer and a target of crizotinib. The objectives of this study were to determine the frequency of ALK rearrangements in a large cohort of patients with primary lung adenocarcinoma and to analyze the association of ALK rearrangements with clinicopathological characteristics and clinical outcomes. The roles of fluorescence in situ hybridization (FISH), Ventana immunohistochemistry (IHC), and reverse transcriptase polymerase chain reaction (RT-PCR) in the detection of ALK rearrangements were evaluated. The ALK rearrangement was detected in 430 specimens from individual patients with primary lung adenocarcinoma using FISH and Ventana IHC based on tissue microarrays. The EGFR status was detected in all of the specimens through DNA sequencing. An RT-PCR was performed on 200 of the specimens and confirmed by sequencing. Of the 430 patients, 46 (10.7%) harbored ALK rearrangements. The ALK rearrangements were associated with a younger age and the EGFR wild type in comparison with ALK-negative patients. The sensitivity and specificity of the Ventana IHC were 100% and 98.2%, respectively, and the concordance rate between the FISH and the Ventana IHC was 98.4%. The sensitivity and specificity of RT-PCR were 95.5% and 87.0%, respectively, and the concordance rate between the FISH and the RT-PCR was 89.0%. The Cox analysis indicated that an early stage and EGFR-activating mutations were independently associated with a longer OS. This study demonstrated that ALK rearrangements are associated with a younger age and the EGFR wild type rather than with other clinicopathological factors. Although the FISH and Ventana IHC have better concordance, and RT-PCR is a more sensitive method and can identify different variants or partners, the IHC and RT-PCR need to be further evaluated in clinical trials to identify their roles in guiding patients' targeted therapy using crizotinib.
Anaplastic Lymphoma Kinase-Positive Adenocarcinoma of Lung:A Cytopathologic Analysis

Ying Chen,Lili Gao,YanLi Wang,Xian Gui,Hao Zhang,Longfu Wang,Lianghong Gu,Liqing Feng,Jiawen Wu,Wentao Yang,Yiju Song,Huan Zeng,Jing Zhang,Qianming Bai,Xiaoyan Zhou,Bo Ping

DOI: https://doi.org/10.3760/cma.j.issn.0529-5807.2015.09.004

2015-01-01

Abstract:Objective To study the cytomorphologic features of anaplastic lymphoma kinase ( ALK )-rearranged pulmonary adenocarcinoma.Methods The morphologic features in 153 pulmonary adenocarcinoma cytology specimens encountered during the period from September, 2011 to April, 2015 in Shanghai Cancer Hospital were retrospectively reviewed.Fluorescence in-situ hybridization ( FISH) and/or immunohistochemistry ( Ventana D5F3) for ALK gene rearrangement were carried out.The samples studied included 34 pleural effusion specimens, 40 endobronchial ultrasound-guided transbronchial needle aspirates ( EBUS-TBNA) and 79 fine needle aspirates of palpable masses on body surface.Results Thirty-nine cases (25.5%) of ALK-rearranged samples were identified by FISH and/or immunohistochemistry, including 3 cases diagnosed by FISH and 36 cases by both technologies.The median age of the ALK-positive group was 50 years, significantly younger than that of the ALK-negative group (60 years old,P=0.002) .Only 4 of the ALK-positive patients were smokers, which was significantly less than that of the ALK-negative group (P<0.01).In ALK-positive group, 3 cases showed cribriform pattern with prominent nucleoli, 3 cases showed cribriform pattern with mucin-rich cells and 8 cases showed extracellular mucus with mucin-rich cells.The above cytomorphologic patterns were significantly less common in ALK-negative tumors ( P <0.01 ) . Conclusions ALK-rearranged lung adenocarcinoma is associated with certain distinctive morphologic patterns, including cribriform architecture, presence of prominent nucleoli, mucin-rich cells and extracellular mucus, which can be observed in cytology specimens ( including conventional smears and cell block sections) .These findings, when combined with clinical features, may give clues to detection of ALK-positive cases.
Comparison of ALK Status Between Primary and Corresponding Lymph Node Metastatic Tumors in Lung Cancer Patients

Qiqi Gao,Honghai Ma,Bo Wang,Yake Yao,Jianya Zhou,Jianying Zhou

DOI: https://doi.org/10.18632/oncotarget.22294

2017-01-01

Oncotarget

Abstract:Background: The anaplastic lymphoma kinase (ALK) protein has recently become a promising target in the treatment of non-small cell lung carcinomas(NSCLC) patients with ALK translocation because of the high response rates obtained with an ALK inhibitor. ALK translocations are present in approximately 3-5% of NSCLC patients. According to the literature, little information about the relationship of ALK status between the primary tumor and metastatic sites has been reported. We intended to determine whether the ALK translocations of primary lung cancers are consistent with those in corresponding metastatic lymph node tumors. Materials and Methods: We analyzed ALK translocations from paired primary and metastatic lymph node tumors in 78 lung cancer patients who had not received TKI before the tissues were sampled. Results: Using fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) methods, all 45 patients with ALK translocation-positive primary lung tumors had translocations in the metastases. For 33 patients who were ALK negative in the primary tumors, 1 (3%) was ALK positive in their metastatic tumors. Conclusion: According to a paired t-test, there is no significant difference between primary lung tumors and metastatic sites. Analysis of ALK translocations in the primary lung tumor would be suitable for planning the use of a TKI for advanced NSCLC, but it would be better to detect metastasis specimens as ALK negative specimens if both primary and metastatic specimens have developed.
Structure of Pfu Pop5, an archaeal RNase P protein.

Ross C. Wilson,Christopher J. Bohlen,M. Foster,C. Bell

DOI: https://doi.org/10.1073/PNAS.0508004103

2006-01-24

Abstract:We have used NMR spectroscopy and x-ray crystallography to determine the three-dimensional structure of PF1378 (Pfu Pop5), one of four protein subunits of archaeal RNase P that shares a homolog in the eukaryotic enzyme. RNase P is an essential and ubiquitous ribonucleoprotein enzyme required for maturation of tRNA. In bacteria, the enzyme's RNA subunit is responsible for cleaving the single-stranded 5' leader sequence of precursor tRNA molecules (pre-tRNA), whereas the protein subunit assists in substrate binding. Although in bacteria the RNase P holoenzyme consists of one large catalytic RNA and one small protein subunit, in archaea and eukarya the enzyme contains several (> or =4) protein subunits, each of which lacks sequence similarity to the bacterial protein. The functional role of the proteins is poorly understood, as is the increased complexity in comparison to the bacterial enzyme. Pfu Pop5 has been directly implicated in catalysis by the observation that it pairs with PF1914 (Pfu Rpp30) to functionally reconstitute the catalytic domain of the RNA subunit. The protein adopts an alpha-beta sandwich fold highly homologous to the single-stranded RNA binding RRM domain. Furthermore, the three-dimensional arrangement of Pfu Pop5's structural elements is remarkably similar to that of the bacterial protein subunit. NMR spectra have been used to map the interaction of Pop5 with Pfu Rpp30. The data presented permit tantalizing hypotheses regarding the role of this protein subunit shared by archaeal and eukaryotic RNase P.
Anaplastic lymphoma kinase fusion gene expression, clinical pathological characteristics and prognosis in 95 Chinese patients with non-small cell lung cancer]

Meng-xue Zhang,Fei Pei,Tian-li Wang,Xiang Han,Jiang-feng You,Peng-cheng Zou,Yue-qi Wang,Xu-wen Li,Xin Liu,Hao-hao Zhong,Yan Liu,Yu-xiang Wang,Hua Wang,Bo Zhang

DOI: https://doi.org/10.3969/j.issn.1671-167X.2014.04.021

2014-01-01

Abstract:To examine the prevalence of anaplastic lymphoma kinase (ALK) fusion gene in Chinese patients with non-small cell lung cancer (NSCLC).In this study, 95 patients with NSCLC and corresponding clinical information and formalin-fixed paraffin-embedded (FFPE) tissue blocks were included. Hematoxylin & eosin (HE) staining, conventional ALK immunochemistry (IHC) staining and intercalated antibody-enhanced polymer (iAEP) IHC staining, and dual-color split fluorescence in situ hybridization (FISH) for ALK fusion gene were performed.Eight ALK-positive cases were detected using anti-ALK immunohistochemistry with the iAEP method, and FISH analyses revealed 4 patients of them who harbored the ALK fusion gene (4.2%, 4/95), including 2 cases of female patients with solid signet-ring cell adenocarcinoma and 2 cases of male patients with adenosquamous carcinoma. The positive cases were all non-smokers without EGFR/KRAS mutations. Furthermore, the positive cases all survived, and the overall postsurgery survival time of 2 cases was more than 5 years.ALK IHC with the iAEP method is better than conventional ALK IHC, and the percentage of the positive cells is more important than that of the intensity. ALK translocations were infrequent in the entire NSCLC patient population (<5%) with better prognosis.
Clinical Characteristics and Progression of Pre-/Minimally Invasive Lung Adenocarcinoma Harboring ALK or RET Rearrangements: a Retrospective Cohort Study.

Chaoqiang Deng,Zongwei Chen,Jinsong Bai,Fangqiu Fu,Shengping Wang,Yuan Li,Yang Zhang,Haiquan Chen

DOI: https://doi.org/10.21037/tlcr-23-517

2023-01-01

Translational Lung Cancer Research

Abstract:Background:Patients harboring anaplastic lymphoma kinase (ALK) or rearranged during transfection (RET) rearrangements are usually diagnosed at a relatively late stage with nodal and distant metastasis, and rapid progression course of ALK/RET fusion-positive lung cancer were well-known. However, clinical characteristics and course of pre-/minimally invasive lung adenocarcinoma harboring ALK or RET fusions are poorly described. Identifying patients with gene fusions at early stage may offer surgical options that could cure those patients.Methods:We retrospectively included patients with surgically resected pre-/minimally invasive lung adenocarcinomas harboring epidermal growth factor receptor (EGFR) mutations or ALK/RET rearrangements, and further compared the patient clinical characteristics, nodule natural course, and survival outcomes. Radiological characteristics including ground-glass component, cystic airspace, pleural attachment, etc. were specially assessed for this study. EGFR (exons 18-22) was detected by Sanger sequencing and quantitative real-time polymerase chain reaction (qRT-PCR) was used to analyze the ALK/RET rearrangements. Lung cancer-specific survival (LCSS), relapse-free survival (RFS), and overall survival (OS) were all evaluated.Results:Of 238 patients with pre-/minimally invasive lung adenocarcinomas, 226 patients had EGFR mutations, 7 patients had ALK fusions, and 5 patients had RET fusions. Average age at surgery was 45.3 years for ALK/RET-positive group and 52.6 years for EGFR-positive group (P=0.049). Radiologically, among the 12 patients with ALK/RET fusions, the majority of lesions (10/12) manifested as mixed ground-glass opacities (mGGOs), which was significantly more prevalent when compared with patients with EGFR mutations (83.4% vs. 24.3%, P<0.001). Moreover, a substantial proportion of cystic airspace was found in ALK/RET-positive group but not in EGFR-positive group (66.7% vs. 14.2%, P<0.001). Among four patients with ALK/RET fusions undergoing surveillance over 1 year before surgery, two of them developed rapid radiologic progression. The 5-year LCSS and RFS were 100%, 100% for ALK/RET-positive group, and 100%, 100% for EGFR-positive group, respectively.Conclusions:ALK/RET-positive pre-/minimally invasive lung adenocarcinomas were mostly characterized as mGGOs with cystic airspace developing rapid nodule progression, and no recurrence occurred during long-term follow-up after resection. This provides insights into proper curative surgery timing in the management of patients with gene fusions. However, these findings must be treated with caution and validated in future multi-center studies with larger sample size.
Clinicopathologic Characteristics of ALK Rearrangements in Primary Lung Adenocarcinoma with Identified EGFR and KRAS Status.

Jinghui Wang,Yujie Dong,Yiran Cai,Lijuan Zhou,Shafei Wu,Guimei Liu,Dan Su,Xi Li,Na Qin,Jingying Nong,Hongyan Jia,Quan Zhang,Jing Mu,Xuan Zeng,Haiqing Zhang,Shucai Zhang,Zongde Zhang

DOI: https://doi.org/10.1007/s00432-014-1584-8

2014-01-01

Journal of Cancer Research and Clinical Oncology

Abstract:PURPOSE:EGFR and KRAS genes and ALK arrangements are three genetic drivers of lung adenocarcinoma. The aim of this study was to investigate the clinicopathologic characteristics of the ALK rearrangements in patients with primary lung adenocarcinoma and with identified EGFR or KRAS status.METHODS:Patients with primary lung adenocarcinoma who had enough tissue for study were enrolled. EGFR and KRAS status were identified by DNA sequencing. ALK rearrangements were detected in a tissue microarray by using fluorescent in situ hybridization.RESULTS:Of 332 patients with primary lung adenocarcinoma, the frequency of the EGFR or the KRAS mutations, and the ALK rearrangements were 44.9% (149/332), 7.2% (24/332), and 9.6% (32/332), respectively. Only one (1/332, 0.3%) patient had the coexistence of the EGFR mutation (L858R at exon 21) and the ALK rearrangement. Compared with ALK-negative patients, ALK-positive patients were significantly younger (P < 0.001). The incidence of the ALK rearrangements was much higher in EGFR wild-type patients than in those with EGFR mutations (P < 0.001). There was no difference in the gender, smoking, disease stage, or histologic subtypes between the ALK-positive patients and the ALK-negative patients.CONCLUSIONS:The ALK rearrangements are independently associated with younger age and the EGFR wild type. The EGFR mutations and the ALK rearrangements are rarely coexistent. The ALK rearrangements and the KRAS mutations are mutually exclusive.
ALK-rearranged Renal Cell Carcinoma: a Multi-Institutional Study of Nine Cases with Expanding the Morphologic and Molecular Genetic Spectrum

Ming Zhao,Xiaona Yin,Xiaoqun Yang,Hualei Gan,Ni Chen,Guangjie Duan,Yanfeng Bai,Xiaodong Teng,Jiayun Xu,Rong Fang,Suying Wang,Shan Zhong,Xiaotong Wang,Lisong Teng

DOI: https://doi.org/10.1016/j.modpat.2024.100536

IF: 8.209

2024-01-01

Modern Pathology

Abstract:ALK -rearranged renal cell carcinoma (ALK-RCC) is rare, molecularly de fined RCC subtype in the recently published fifth edition of World Health Organization classi fication of tumors. In this study, we described 9 ALK-RCCs from a clinicopathologic, immunohistochemical, and molecular genetic aspect, supporting and extending upon the observations by previous studies regarding this rare subgroup of RCC. There were 6 male and 3 female patients with ages ranging from 14 to 59 years (mean, 34.4 years). None of the patients had sickle cell trait. The diagnosis was based on radical or partial nephrectomy specimen for 8 patients and on biopsy specimen for 1. Tumor size ranged from 2.5 to 7.2 cm (mean, 2.8 cm). Follow-up was available for 6 of 9 patients (6-36 months); 5 had no tumor recurrence or metastasis and 1 developed lung metastasis at 24 months. The patient was subsequently treated with resection of the metastatic tumor followed by crizotinib-targeted therapy, and he was alive without tumor 12 months later. Histologically, the tumors showed a mixed growth of multiple patterns, including papillary, solid, tubular, tubulocystic, cribriform, and corded, often set in a mucinous background. The neoplastic cells had predominantly eosinophilic cytoplasm. Focally, clear cytoplasm with polarized nuclei and subnuclear vacuoles (n = 1), and pale foamy cytoplasm (n = 1) were observed on the tumor cells. The biopsied tumor showed solid growth of elongated tubules merging with bland spindle cells. Other common and uncommon features included psammomatous microcalci fications (n = 5), rhabdoid cells (n = 4), prominent intracytoplasmic vacuoles (n = 4), prominent chronic in flammatory in filtrate (n = 3), signet ring cell morphology (n = 2), and pleomorphic cells (n = 2). By immunohistochemistry, all 9 tumors were diffusely positive for ALK(5A4) and 4 of 8 tested cases showed reactivity for TFE3 protein. By fluorescence in situ hybridization analysis, ALK rearrangement was identi fied in all the 9 tumors; none of the tested tumors harbored TFE3 rearrangement (0/4) or gains of chromosomes 7 and 17 (0/3). ALK fusion partners were identi fied by RNA-sequencing in all 8 cases analyzed, including EML4 (n = 2), STRN (n = 1), TPM3 (n = 1), KIF5B (n = 1), HOOK1 (n = 1), SLIT1 (n = 1), and TPM1 (3'UTR) (n = 1). Our study further expands the morphologic and molecular genetic spectrum of ALK-RCC. (c) 2024 United States & Canadian Academy of Pathology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
Comparative analysis of clinicoradiologic characteristics of lung adenocarcinomas with ALK rearrangements or EGFR mutations

J. Y. Zhou,J. Zheng,Z. F. Yu,W. B. Xiao,J. Zhao,K. Sun,B. Wang,X. Chen,L. N. Jiang,W. Ding,J. Y. Zhou

DOI: https://doi.org/10.1007/s00330-014-3516-z

IF: 7.034

2015-01-01

European Radiology

Abstract:Objective To compare the clinicoradiologic features of tumours with echinoderm anaplastic lymphoma kinase ( ALK ) rearrangements, epidermal growth factor receptor ( EGFR ) mutations, or wild type (WT) for both genes in a cohort of patients with lung adenocarcinoma to identify useful characteristics of different gene statuses. Methods In 346 lung adenocarcinoma patients, ALK rearrangements were confirmed with fluorescence in situ hybridisation, and EGFR mutations were determined by pyrosequencing assay. Patients were divided into three groups: ALK rearrangement (ALK+ group, n = 48), EGFR mutation (EGFR+ group, n = 166), and WT for both genes (WT group, n = 132). Chest computed tomography (CT) examinations were performed in all patients. The percentages of ground-glass opacity volume (pGGO) and tumour shadow disappearance rate (TDR) were measured using semi-automated nodule assessment software. Results The pGGO was significantly lower in the ALK+ group (25.1 % ± 24.3) than in the EGFR+ group (37.2 % ± 25.7, p < 0.001) and the WT group (36.1 % ± 24.6, p = 0.001). The TDR in the ALK+ group (17.3 % ± 25.1) was significantly lower than in the EGFR+ group (26.8 % ± 24.9, p = 0.002) and the WT group (25.7 % ± 24.6, p = 0.003). Conclusions Solid pattern with lower incidence of lobulated border, finely spiculated margins, pleural retraction, and bubble-like lucency on CT imaging are the main characteristics of ALK rearrangement tumours. Key Points • EGFR/ALK testing is recommended for lung adenocarcinoma patients for EGFR/ALK-targeted TKI therapy . • EGFR /ALK testing is restricted by limited tissue samples and cost pressures . • Lower pGGO and TDR are the main clinicoradiological characteristics of ALK+ tumours . • pGGO and TDR are predictive factors for selecting patients for ALK/EGFR testing .
Real‐world data on ALK rearrangement test in Chinese advanced non‐small cell lung cancer (RATICAL): a nationwide multicenter retrospective study

Lin Li,Wencai Li,Chunyan Wu,Yanfeng Xi,Lei Guo,Yuan Ji,Lili Jiang,Ji Li,Jingping Yun,Gang Chen,Yuan Li,Yueping Liu,Dianbin Mu,Yuchen Han,Leina Sun,Qingxin Xia,Xiaodong Teng,Nanying Che,Wei Wu,Xueshan Qiu,Chao Liu,Xiaochu Yan,Daiqiang Li,Zhihong Zhang,Zhe Wang,Yujun Li,Zheng Wang,Lingchuan Guo,Xiu Nie,Jingshu Geng,Jianhua Zhou,Jianming Ying

DOI: https://doi.org/10.1002/cac2.12593

IF: 15.2825

2024-07-17

Cancer Communications

Abstract:Abstract Background Anaplastic lymphoma kinase ( ALK ) test in advanced non‐small cell lung cancer (NSCLC) can help physicians provide target therapies for patients harboring ALK gene rearrangement. This study aimed to investigate the real‐world test patterns and positive rates of ALK gene rearrangements in advanced NSCLC. Methods In this real‐world study (ChiCTR2000030266), patients with advanced NSCLC who underwent an ALK rearrangement test in 30 medical centers in China between October 1, 2018 and December 31, 2019 were retrospectively analyzed. Interpretation training was conducted before the study was initiated. Quality controls were performed at participating centers using immunohistochemistry (IHC)‐VENTANA‐D5F3. The positive ALK gene rearrangement rate and consistency rate were calculated. The associated clinicopathological characteristics of ALK gene rearrangement were investigated as well. Results The overall ALK gene rearrangement rate was 6.7% in 23,689 patients with advanced NSCLC and 8.2% in 17,436 patients with advanced lung adenocarcinoma. The quality control analysis of IHC‐VENTANA‐D5F3 revealed an intra‐hospital consistency rate of 98.2% (879/895) and an inter‐hospital consistency rate of 99.2% (646/651). IHC‐VENTANA‐D5F3 was used in 53.6%, real‐time polymerase chain reaction (RT‐PCR) in 25.4%, next‐generation sequencing (NGS) in 18.3%, and fluorescence in‐situ hybridization (FISH) in 15.9% in the adenocarcinoma subgroup. For specimens tested with multiple methods, the consistency rates confirmed by IHC‐VENTANA‐D5F3 were 98.0% (822/839) for FISH, 98.7% (1,222/1,238) for NGS, and 91.3% (146/160) for RT‐PCR. The overall ALK gene rearrangement rates were higher in females, patients of ≤ 35 years old, never smokers, tumor cellularity of > 50, and metastatic specimens used for testing in the total NSCLC population and adenocarcinoma subgroup (all P < 0.05). Conclusions This study highlights the real‐world variability and challenges of ALK test in advanced NSCLC, demonstrating a predominant use of IHC‐VENTANA‐D5F3 with high consistency and distinct clinicopathological features in ALK ‐positive patients. These findings underscore the need for a consensus on optimal test practices and support the development of refined ALK test strategies to enhance diagnostic accuracy and therapeutic decision‐making in NSCLC.

oncology
Prevalence and clinicopathological characteristics of ALK fusion subtypes in lung adenocarcinomas from Chinese populations

Difan Zheng,Rui Wang,Yang Zhang,Yunjian Pan,Xinghua Cheng,Chao Cheng,Shanbo Zheng,Hang Li,Ranxia Gong,Yuan Li,Xuxia Shen,Yihua Sun,Haiquan Chen

DOI: https://doi.org/10.1007/s00432-015-2081-4

Abstract:Purpose: We performed this retrospective study to have a comprehensive investigation of the clinicopathological characteristics of ALK fusion-positive lung adenocarcinoma in Chinese populations. Methods: We screened 1407 patients with primary lung adenocarcinoma from October 2007 to May 2013. Quantitative real-time PCR (qRT-PCR), reverse transcriptase PCR (RT-PCR), and fluorescence in situ hybridization were performed to detect ALK fusion genes, with validation of positive results using immunohistochemistry. Clinicopathological characteristics were collected to assess prognosis in ALK fusion-positive patients. Results: Of 1407 patients with lung adenocarcinoma, there were 74 (5.3 %) ALK fusion-positive patients. Patients harboring ALK fusion were significantly younger (56.0 years vs. 59.8 years p = 0.002) and were more likely to have advanced stages (stage III or stage IV) (OR 1.761; 95 % CI 1.10-2.82, p = 0.017). Lepidic predominant adenocarcinoma was rarely found in ALK fusion patients (2.7 vs. 13.5 % p = 0.025), while IMA (invasive mucinous adenocarcinoma) predominant adenocarcinoma was more frequently found (21.6 vs. 5.0 % p < 0.001). ALK fusion was neither a risk factor nor protective factor in relapse-free survival and overall survival. Male, current smoker, and EML4-ALK variant 3 indicated poor prognosis among ALK fusion-positive lung adenocarcinomas. Conclusions: ALK fusion was detected in 5.3 % (74/1407) of the Chinese patients with lung adenocarcinoma. ALK fusion defines a molecular subset of lung adenocarcinoma with unique clinicopathological characteristics. Different ALK fusion variants determine distinct prognoses.
P1.03-04 Molecular Characteristics of ALK Primary Point Mutations Non-Small-Cell Lung Cancer in Chinese Patients

J. Lai,W. Wang,C. Xu,Q. Zhang,W. Zhuang,Y. Huang,Y. Zhu,Y. Chen,G. Chen,M. Fang,T. Lv,Y. Song

DOI: https://doi.org/10.1016/j.jtho.2018.08.685

IF: 20.121

2018-01-01

Journal of Thoracic Oncology

Abstract:Anaplastic lymphoma kinase (ALK) gene rearrangements have been identified in lung cancer at 3-7% frequency, thus representing an important subset of genetic lesions that drive oncogenesis in this disease. While the genetic locus of ALK primary point mutations NSCLC patients is unclear. The aim of this study is to investigate mutations and prognosis of NSCLC harboring ALK primary point mutations. A total of 339 patients with non-small-cell lung cancer were recruited between July 2012 and December 2015. The status of ALK primary point mutation and other genes were detected by next generation sequencing. ALK gene primary point mutation rate was 8.55% (29/339) in non-small cell lung cancer, including V163L (3 patients), F921Gfs*16 (2 patients), K1416N (2 patients), A585T (2 patients), P1442Q (1 patient), A348T (1 patient), K1525E (1 patient), S737L (1 patient), P115L (1 patient), Q515E (1 patient), E314D (1 patient), R395H (1 patient), S1219F (1 patient), S341G (1 patient), P1543S (1 patient), G129V (1 patient), Q167H (1 patient), L550F (1 patient), T1012M (1 patient), D302Y (1 patient), H755Q (1 patient), H331Q (1 patient), G1474E (1 patient) and E119D (1 patient), and median overall survival (OS) for these patients was 20.0 months. Among them, 27 patients with co-occurring mutations had a median OS of 20.0 months, and median OS of the 2 patients without complex mutations was 8.5 months. Statistically significant difference was found between the two groups (P=0.02). Briefly, patients with (n=8) or without (n=21) co-occurring EGFR mutations had a median OS of 24.0 months and 20.0 months respectively (P=0.73); patients with (n=21) or without (n=8) co-occurring TP53 mutations had a median OS of 20.0 months and 17.0 months respectively (P=0.83). EGFR and TP53 gene accompanied may have less correlation with ALK primary point mutation in NSCLC patients. Results of ongoing studies will provide a platform for further research to offer individualized therapy with the purpose of improving outcomes.
Comparative studies on Salmonella typhi grown in vivo and in vitro II. The effect of extracts from normal and infected organs on the bactericidal serum action on strains grown in vivo and in vitro

A. Olitzki,O. Kaplan

DOI: https://doi.org/10.1017/S0022172400020702

1963-03-01

Journal of Hygiene

Abstract:The sensitivity of in vitro- and in vivo-grown strains of S. typhi was determined not only by their antigenic structure, but also by their growth phase. An increased vulnerability to the antibody-complement system has been found in cells during the lag and the early exponential phase, while non-multiplying cells devoid of any nutrient were almost invulnerable to the antibody-complement system. Extracts of organs from normal and infected animals may promote the growth of S. typhi, and, therefore, increase its vulnerability to the antibody-complement system. The majority of extracts from organs of mice infected with strain Ty 2 inhibited markedly the bactericidal action of serum on this strain and, to a lower extent, on strain O 901.
Molecular and clinical analysis of Chinese patients with anaplastic lymphoma kinase ( <i> <scp>ALK</scp> </i> )‐rearranged non‐small cell lung cancer

Xiaoyun Zhou,Jiawei Shou,Jin Sheng,Chunwei Xu,Shengxiang Ren,Xiuyu Cai,Qian Chu,Wenxian Wang,Qinhong Zhen,Yuefen Zhou,Wenfeng Li,Hong Pan,Hongsen Li,Tao Sun,Huanqing Cheng,Huina Wang,Feng Lou,Chuangzhou Rao,Shanbo Cao,Hongming Pan,Yong Fang

DOI: https://doi.org/10.1111/cas.14177

IF: 5.7

2019-01-01

Cancer Science

Abstract:Anaplastic lymphoma kinase ( ALK ) fusions have been recognized as a therapeutic target in non‐small cell lung cancer ( NSCLC ). However, molecular signatures and clinical characteristics of the Chinese population with ALK ‐rearranged NSCLC are not well elucidated. In the present study, we carried out targeted next‐generation sequencing on tissue and plasma ct DNA samples in 1688 patients with NSCLC . Overall, ALK fusions were detected in 70 patients (4.1%), and the frequencies of ALK fusions detected in tissue and plasma samples were 5.1% and 3.3%, respectively. Additionally, the prevalence of breakpoint locations for EML 4‐ ALK fusions in ct DNA was significantly correlated with that in tumor tissues ( R 2 = .91, P = .045). According to age, the incidence rates of ALK fusions among young (age <45 years), middle‐aged (between 45 and 70 years) and elderly (>70 years) patients were significantly different ( P < .001). In 70 ALK ‐rearranged cases, coexistence of epidermal growth factor receptor ( EGFR ) alterations and ALK fusions was detected in 12 cases (17.1%) and EGFR mutations tended to coexist with non‐ EML 4‐ ALK rearrangements. Notably, novel ALK fusion partners, including TRIM 66 , SWAP 70 , WNK 3 , ERC 1 , TCF 12 and FBN 1 were identified in the present study. Among EML 4 ‐ ALK fusion variants, patients with variant V1 were younger than patients with variant V3 ( P = .023), and TP 53 mutations were more frequently concurrent with variant V3 compared with variant V1 ( P = .009). In conclusion, these findings provide new insights into the molecular‐clinical profiles of patients with ALK ‐rearranged NSCLC that may improve the treatment strategy of this population.
Antisense RNA regulation of the pAD1 par post‐segregational killing system requires interaction at the 5′ and 3′ ends of the RNAs

Tony J. Greenfield,K. Weaver

DOI: https://doi.org/10.1046/j.1365-2958.2000.02034.x

2000-08-01

Molecular Microbiology

Abstract:The par stability determinant of the Enterococcus faecalis plasmid pAD1 is the first antisense RNA‐regulated post‐segregational killing system (PSK) identified in a Gram‐positive organism. Par encodes two small, convergently transcribed RNAs, designated RNA I and RNA II, which are the toxin and antidote of the par PSK system respectively. RNA I encodes an open reading frame for a 33‐amino‐acid toxin called Fst. Expression of fst is regulated post‐transcriptionally by RNA II. In this paper, RNA II is shown to interact with RNA I by a unique antisense RNA mechanism. RNA I and RNA II contain complementary direct repeats at their 5′ ends and a complementary transcriptional terminator stem–loop at their 3′ ends. Deletion of the terminator or mutations within the terminator loop of RNA II severely reduced the rate of interaction in vitro. Mutations in the 5′ direct repeats of RNA II prevented the RNAs from interacting in vitro. For these mutations in RNA II, complementary mutations in RNA I were shown to restore interaction. The reduced binding efficiency of the RNA II mutants was paralleled by the failure of these mutants to suppress par‐mediated killing in vivo. These results indicate that regions at both the 5′ and the 3′ ends of the par transcripts are important for RNA I–RNA II interaction.
Alk-Rearranged Lung Cancer In Chinese: A Comprehensive Assessment Of Clinicopathology, Ihc, Fish And Rt-Pcr

Yuan Li,Yunjian Pan,Rui Wang,Yihua Sun,Haichuan Hu,Xuxia Shen,Yongming Lu,Lei Shen,Xiongzeng Zhu,Haiquan Chen

DOI: https://doi.org/10.1371/journal.pone.0069016

IF: 3.7

2013-01-01

PLoS ONE

Abstract:Approximately 3-7% of non-small cell lung cancers harbor an anaplastic lymphoma kinase (ALK) gene fusion, constituting a new molecular subtype of lung cancer that responds to crizotinib, an ALK inhibitor. Although previous studies have evaluated ALK-rearranged lung cancers, the comprehensive analysis of lung cancer in Chinese has not well assessed. Herein, we identified 44 cases of ALK-rearranged samples by fluorescent in-situ hybridization (FISH), immunohistochemistry (IHC), and reverse transcription polymerase chain reaction (RT-PCR) in a large number of surgically resected lung cancers. All 44 ALK-rearranged lung cancers were adenocarcinomas, with 2 cases having additional focal squamous components. The goal was to analyse the clinicopathological features of ALK-rearranged lung adenocarcinomas. Our data showed that a cribriform structure, prominent extracellular mucus and any type of mucous cell pattern may be either sensitive or specific to predict an ALK rearrangement. We used FISH as the standard detection method. We compared the ALK rearrangement accuracy of FISH, RT-PCR and IHC. RT-PCR could define both the ALK fusion partner and the fusion variant, but seemed unable to detect all translocations involving the ALK gene. It is noteworthy that IHC using the D5F3 antibody (Cell Signaling Technology) showed higher sensitivity and specificity than the ALK1 antibody (Dako). Therefore, we conclude that IHC remains a cost-effective and efficient technique for diagnosing ALK rearrangements and that D5F3 can be the optimal screening antibody in clinical practice.
Comparison of clinical and radiological characteristics between anaplastic lymphoma kinase rearrangement and epidermal growth factor receptor mutation in treatment naïve advanced lung adenocarcinoma.

Yingying Miao,Suhua Zhu,Huijuan Li,Jiawei Zou,Qingqing Zhu,Tangfeng Lv,Yong Song

DOI: https://doi.org/10.21037/jtd.2017.08.134

2017-01-01

Journal of Thoracic Disease

Abstract:Background: Gene analysis could not be performed in all patients, especially in advanced non-small cell lung cancer (NSCLC). We aimed to find some clinical futures and CT or FDG-PET characteristics, which could be combined to help distinguish anaplastic lymphoma kinase (ALK) rearrangement form epidermal growth factor receptor (EGFR) mutations in treatment naive advanced lung adenocarcinoma of Chinese patients. Methods: We retrospectively reviewed clinical and radiological characteristics of 145 patients with treatment naive advanced lung adenocarcinoma. The one-way ANOVA, the Mann-Whitney test, chi-square test and logistic regression were used for comparison between patients with ALK rearrangement and those with EGFR mutation. Results: Among 145 patients with advanced lung adenocarcinoma, only six patients had both ALK rearrangement and EGFR mutation, the sample size was too small to analysis. Univariate analysis revealed that patients with ALK rearrangement were younger (P=0.001) and with lower serum carcinoembryonic antigen (CEA) level (P=0.008) than those with EGFR mutation. More of tumors with ALK rearrangement were well defined (P=0.023) and have bubble lucency (P=0.026) compared with those with EGFR mutation (P=0.026). Lymphadenopathy was seen more frequently in patients with ALK rearrangement (P=0.167). Twenty-six patients received FDG-PET/CT, among this population, lesion standardized uptake values (SUV) >6.95 and lymph nodes SUVmax >6.25 were more often seen in ALK rearrangement group (P=0.011, both). In multivariate analysis, patients younger than 50 years (RR= 9.878, 95% CI: 2.318-42.090, P=0.002), with lower CEA level than 4.95 mu g/L (RR = 8.166, 95% CI: 1.085-31.983, P=0.003)and without brain metastasis (RR = 7.304, 95% CI: 1.099-48.558, P=0.040)were more likely to be ALK rearrangement than EGFR mutation. Tumor diameter less than 36 mm were prone to be EGFR mutation (RR = 0.078, 95% CI: 0.0170.356, P=0.001). Conclusions: Treatment naive advanced lung adenocarcinomas with ALK rearrangement were more likely to have younger age, lower serum CEA level, larger tumor volume, well defined tumor border, and non-brain metastasis than those with EGFR mutation. Bubble lucency and higher FDG uptake of lesion and lymph nodes may help distinguish ALK rearrangement from EGFR mutation in the absence of genetic analysis.

Observations on neonatal mortality.

Dissecting the Clinicopathological, Genomic, and Prognostic Significance of ALK Rearrangement in Resected Lung Adenocarcinoma

Concomitant Mutation Status of ALK-rearranged Non-Small Cell Lung Cancers and Its Prognostic Impact on Patients Treated with Crizotinib

Clinicopathological and prognostic implications of ALK rearrangement in patients with completely surgically resected lung adenocarcinoma

Clinical Characteristics and Outcomes of Patients with Primary Lung Adenocarcinoma Harboring Alk Rearrangements Detected by Fish, Ihc, and Rt-Pcr

Anaplastic Lymphoma Kinase-Positive Adenocarcinoma of Lung:A Cytopathologic Analysis

Comparison of ALK Status Between Primary and Corresponding Lymph Node Metastatic Tumors in Lung Cancer Patients

Structure of Pfu Pop5, an archaeal RNase P protein.

Anaplastic lymphoma kinase fusion gene expression, clinical pathological characteristics and prognosis in 95 Chinese patients with non-small cell lung cancer]

Clinical Characteristics and Progression of Pre-/Minimally Invasive Lung Adenocarcinoma Harboring ALK or RET Rearrangements: a Retrospective Cohort Study.

Clinicopathologic Characteristics of ALK Rearrangements in Primary Lung Adenocarcinoma with Identified EGFR and KRAS Status.

ALK-rearranged Renal Cell Carcinoma: a Multi-Institutional Study of Nine Cases with Expanding the Morphologic and Molecular Genetic Spectrum

Comparative analysis of clinicoradiologic characteristics of lung adenocarcinomas with ALK rearrangements or EGFR mutations

Real‐world data on ALK rearrangement test in Chinese advanced non‐small cell lung cancer (RATICAL): a nationwide multicenter retrospective study

Prevalence and clinicopathological characteristics of ALK fusion subtypes in lung adenocarcinomas from Chinese populations

P1.03-04 Molecular Characteristics of ALK Primary Point Mutations Non-Small-Cell Lung Cancer in Chinese Patients

Comparative studies on Salmonella typhi grown in vivo and in vitro II. The effect of extracts from normal and infected organs on the bactericidal serum action on strains grown in vivo and in vitro

Molecular and clinical analysis of Chinese patients with anaplastic lymphoma kinase ( <i> <scp>ALK</scp> </i> )‐rearranged non‐small cell lung cancer

Antisense RNA regulation of the pAD1 par post‐segregational killing system requires interaction at the 5′ and 3′ ends of the RNAs

Alk-Rearranged Lung Cancer In Chinese: A Comprehensive Assessment Of Clinicopathology, Ihc, Fish And Rt-Pcr

Comparison of clinical and radiological characteristics between anaplastic lymphoma kinase rearrangement and epidermal growth factor receptor mutation in treatment naïve advanced lung adenocarcinoma.